Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

Although two growth factor receptors, EGFR and HER2, are amongst the best targets for cancer treatment, no agents targeting HER3, their kinase-defective family member, have so far been approved. Because emergence of resistance of lung tumors to EGFR kinase inhibitors (EGFRi) associates with compensa...

Descripción completa

Detalles Bibliográficos
Autores principales: Romaniello, Donatella, Marrocco, Ilaria, Belugali Nataraj, Nishanth, Ferrer, Irene, Drago-Garcia, Diana, Vaknin, Itay, Oren, Roni, Lindzen, Moshit, Ghosh, Soma, Kreitman, Matthew, Kittel, Jeanette Clarissa, Gaborit, Nadege, Bergado Baez, Gretchen, Sanchez, Belinda, Eilam, Raya, Pikarsky, Eli, Paz-Ares, Luis, Yarden, Yosef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563838/
https://www.ncbi.nlm.nih.gov/pubmed/32847130
http://dx.doi.org/10.3390/cancers12092394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563838/
https://www.ncbi.nlm.nih.gov/pubmed/32847130
http://dx.doi.org/10.3390/cancers12092394

Ejemplares similares